Back to Search
Start Over
Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications.
- Source :
-
International Journal of Geriatric Psychiatry . Mar2000, Vol. 15 Issue 3, p242-247. 6p. 5 Charts. - Publication Year :
- 2000
-
Abstract
- Alzheimer's disease (AD) is often associated with multiple comorbidities and subsequent polypharmacy. Treatment of AD with acetylcholinesterase (AChE) inhibitors can carry a risk of drug interaction with multiple medications often prescribed for other co-existing illnesses. Rivastigmine is an AChE inhibitor that is enzymatically cleaved by AChE, minimally metabolized by cytochrome P450 enzymes, has low protein binding, has a short plasma half-life, and a relatively short duration of action. Such properties make it ideal for use in this patient population. A pharmacodynamic analysis of rivastigmine administered concomitantly with other medications (22 different therapeutic classes) did not reveal any significant pattern of increase in adverse events that would indicate a drug interaction. In summary, rivastigmine was well tolerated and safely administered to a population receiving multiple medications for ‘real-world’ comorbidities. Copyright © 2000 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 08856230
- Volume :
- 15
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- International Journal of Geriatric Psychiatry
- Publication Type :
- Academic Journal
- Accession number :
- 11821301
- Full Text :
- https://doi.org/10.1002/(SICI)1099-1166(200003)15:3<242::AID-GPS110>3.0.CO;2-7